Oxidized LDL Receptor 1 gene polymorphism in patients with Metabolic Syndrome

European Journal of Clinical Investigation

Volumn 43, Issue 1, 2013, Pages 41-48

  Palmieri, Vincenzo O ^a   Coppola, Brigida ^b   Grattagliano, Ignazio ^a   Casieri, Valentina ^b   Cardinale, Giovanna ^a   Portincasa, Piero ^a   Palasciano, Giuseppe ^a   Di Serio, Francesca ^b  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Insulin resistance; LOX 1 polymorphism; Metabolic Syndrome; Microalbuminuria; Thiobarbituric acid; Thioredoxin

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; INSULIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOREDOXIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PATIENT ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; ALBUMINURIA; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; INSULIN RESISTANCE; LIPID PEROXIDATION; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; SCAVENGER RECEPTORS, CLASS E; THIOBARBITURATES; THIOREDOXINS;

EID: 84871607277     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12013     Document Type: Article

References (34)

1. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008;19:491-504.
2. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
3. McNeill AM, Rosamond WD, Girman CJ. The metabolic syndrome and 11- year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.
4. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7.
5. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006;69:36-45.
6. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endotelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002;95:89-100.
7. Murphy JE, Tedbury PR, Homer-Vanniasinkam S. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 2005;182:1-15.
8. Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:1107-15.
9. Li D, Williams V, Liu L, Chen H, Sawamura T, Antakli T et al. LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am J Physiol Heart Circ Physiol 2002;283:H1795-801.
10. Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun 1997;237:496-8.
11. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T et al. Inducible expression of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein, in vascular endothelial cells. Circ Res 1998;83:322-7.
12. Chen M, Nagase M, Fujita T, Narumiya S, Masaki T, Sawamura T. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and age. Biochem Biophys Res Commun 2001;87:962-8.
13. Aoyama T, Sawamura T, Furutani Y, Matsuoka R, Yoshida MC, Fujiwara H et al. Structure and chromosomal assignment of the human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) gene. Biochem J 1999;39:177-84.
14. Mango R, Clementi F, Borgiani P, Forleo GB, Federici M, Contino G et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet 2003;40:933-6.
15. Chen Q, Reis SE, Kammerer C, Craig WY, LaPierre SE, Zimmer EL et al. Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 2003;107:3146-51.
16. Mango R, Biocca S, Del VecchioF, Clementi F, Sangiuolo F, Amati F et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res 2005;97:152-8.
17. Trabetti E, Biscuola M, Cavallari U, Malerba G, Girelli D, Olivieri O et al. On the association of the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction or coronary artery disease. Eur J Hum Genet 2006;14:127-30.
18. Sentinelli F, Filippi E, Fallarino M, Romeo S, Fanelli M, Buzzetti R et al. The 3'-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. Nutr Metab Cardiovasc Dis 2006;16:345-52.
19. Vietri MT, Molinari AM, Boggia M, Parisi M, Cioffi M. IVS4-14 A/G and IVS4-73 C/T Polymorphisms in OLR1 Gene in Patients with Ischemic Cerebrovascular Diseases. Genet Test Molec Biomark 2010;14:9-11.
20. Vecchione L, Gargiul E, Borgiani P, Predazzi I, Mango R, Romeo F et al. Genotyping OLR1 gene: a genomic biomarker for cardiovascular diseases. Recent Patents Cardiovasc Drug Discov 2007;2:147-51.
21. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute, 2001 (NIH publ. no. 01-3670)
22. International Task Force for Prevention of Coronary Heart Disease ( http://www.chd-taskforce.com/coronary_risk_assessment.html). Accessed on January 2012.
23. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 2006;136:3022-6.
24. Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Mutual changes of thioredoxin and nitrosothiols during biliary cirrhosis: results from humans and cholestatic rats. Hepatology 2007;45:331-9.
25. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
26. Renier G. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a relevant target for diabetic vasculopathy? Cardiovasc Hematol Disord Drug Targets 2008;8:203-11.
27. Renie G, Maingrette F, Li L. Diabetic vasculopathy and the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). Curr Diabetes Rev 2007;3:103-10.
28. Musso G, Cassader M, De Michieli F, Saba F, Bo S, Gambino R. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr 2011;94:1033-42.
29. Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 2004;94:892-901.
30. Li L, Sawamura T, Renier G. Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes 2003;52:1843-50.
31. Kita T, Kume N, Ishii K, Horiuchi H, Arai H, Yokode M. Oxidized LDL and expression of monocyte adhesion molecules. Diabetes Res Clin Pract 1999;45:123-6.
32. Tan KC, Shiu SW, Wong Y, Leng L, Bucala R. Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus. J Lipid Res 2008;49:1438-44.
33. Chui PC, Guan HP, Lehrke M, Lazar MA. PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J Clin Invest 2005;115:2244-56.
34. Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G et al. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol 2007;20:646-55.